Home  »  Business   »  Highlights from the Ratings and Financial Report f...

Highlights from the Ratings and Financial Report for Kintara Therapeutics Inc. (KTRA)

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Kintara Therapeutics Inc. (NASDAQ:KTRA) went down by -0.39% from its latest closing price compared to the recent 1-year high of $3.35. The company’s stock price has collected -8.99% of loss in the last five trading sessions. Press Release reported 2 hours ago that Kintara Announces Grant from Luxembourg National Research Fund and Cancer Foundation Luxembourg to Support VAL-083’s Mechanism of Action Research in Glioblastoma

Is It Worth Investing in Kintara Therapeutics Inc. (NASDAQ :KTRA) Right Now?

Plus, the 36-month beta value for KTRA is at 1.57.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


KTRA currently public float of 41.37M and currently shorts hold a 2.18% ratio of that float. Today, the average trading volume of KTRA was 1.56M shares.

KTRA’s Market Performance

KTRA stocks went down by -8.99% for the week, with a monthly drop of -24.53% and a quarterly performance of -47.91%, while its annual performance rate touched -64.93%. The volatility ratio for the week stands at 7.40% while the volatility levels for the past 30 days are set at 7.15% for Kintara Therapeutics Inc.. The simple moving average for the period of the last 20 days is -12.04% for KTRA stocks with a simple moving average of -61.25% for the last 200 days.

KTRA Trading at -28.49% from the 50-Day Moving Average

After a stumble in the market that brought KTRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.19% of loss for the given period.

Volatility was left at 7.15%, however, over the last 30 days, the volatility rate increased by 7.40%, as shares sank -25.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -43.10% lower at present.

During the last 5 trading sessions, KTRA fell by -5.95%, which changed the moving average for the period of 200-days by -72.42% in comparison to the 20-day moving average, which settled at $0.5557. In addition, Kintara Therapeutics Inc. saw -2.35% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at KTRA starting from Praill Anthony Scott, who purchase 28,700 shares at the price of $0.68 back on Dec 08. After this action, Praill Anthony Scott now owns 37,186 shares of Kintara Therapeutics Inc., valued at $19,430 using the latest closing price.

Zarrabian Saiid, the Head of Strategic Partnerships of Kintara Therapeutics Inc., purchase 38,109 shares at $0.64 during a trade that took place back on Dec 07, which means that Zarrabian Saiid is holding 55,500 shares at $24,298 based on the most recent closing price.

>> 7 Top Picks for the Post-Pandemic Economy <<

Leave a Comment

Your email address will not be published. Required fields are marked *




Download Free eBook For


100% free. stop anytime no spam